A new edition of industry news highlights focuses on health technology assessments (HTAs) and their growing acceptance of real world evidence (RWE). These industry highlights are published twice a month in The Journal of Comparative Effectiveness Research. “Read highlights from the latest […]
ICER Announces Cloud-Based ICER Analytics Platform
The Institute for Clinical and Economic Review (ICER) has announced the launch of ICER Analytics. The new cloud-based tool is expected to promote transparency and to make it easier to access ICER’s value assessments. ICER Analytics will also be accessible through Xcenda’s FormularyDecisions […]
ISPOR Publishes Good Practices Report
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) task force has published its Good Practices Report. The purpose of the report is to highlight cost-effectiveness outcomes and to reduce the risk of bias. The International Society for Pharmacoeconomics and Outcomes […]
Cytel Chief Data Officer Discuses HEOR and RWE
Cytel Chief Data Officer & Head of Europe Dr. Radek Wasiak discusses how Cytel has expanded to utilize health economics and outcomes research (HEOR) and real world evidence (RWE). He notes that the COVID-19 pandemic has led to more interest into and recognition of the value of RWE. According […]
HealthVerity RWD Use Case Now Available
The use of real world data (RWD) in the synthetic control arm in clinical trials is becoming essential. HealthVerity provides a use case featuring a leading pharma company that is studying the efficacy of a rare disease drug in preparation for its regulatory submission. The use case highlights how […]
Fate of Biogen’s Alzheimer’s Disease Drug Remains Uncertain
Biogen is awaiting the Food and Drug Administration’s decision regarding its Alzheimer’s disease drug, aducanumab. However, mixed data regarding the drug’s efficacy make approval far from certain. The Institute for Clinical and Economic Review (ICER) noted it had extended its drug assessment […]
ICER Will Consider AstraZeneca Asthma Treatment
The Institute for Clinical and Economic Review (ICER) is set to evaluate AstraZeneca’s tezepelumab. ICER will consider the efficacy and value of the asthma drug. The Food and Drug Administration is expected to rule on the drug later this year or early 2022. “The assessment will be publicly […]
FDA Office of Health Equity Leader Discusses Diversity in Clinical Trials
Associate Commissioner for Minority Health and Director of the Office of Minority Health and Health Equity (OMHHE) at the FDA RADM Richardae Araojo shared her thoughts on the importance of promoting diverse populations to be included in clinical trials. The OMHHE has developed a Diversity in […]
ISPOR Signal Virtual Event on Value and Pricing Strategies
ISPOR will host its second event in its new Signal series on June 25th, from 11:00 AM to 12:00 PM EDT. The virtual event will highlight strategies for showcasing therapeutic value and outcomes. Invited speakers include John G. Singer, executive director of Blue Spoon Consulting and Dr. Alexander […]
Managing Healthcare Risk Effectively During COVID-19
The COVID-19 pandemic has placed immense burden on healthcare systems. A new whitepaper, sponsored by Change Healthcare, provides insight into how to manage this risk. It also lays out how to calculate risk scores. “As pandemic-driven economic instability proliferates and exacerbates pre-pandemic […]
Optum Whitepaper on RWD in Rare Disease Research
Optum is offering a whitepaper that provides insight into how real world data (RWD) can accelerate rare disease research. The paper identifies deidentified patient data, including electronic health records, as a robust source of RWD. “Rare disease research and treatment development is uniquely […]
Woman to Woman Podcast Series Highlights Senior HEOR Researcher
Divya Yerraguntla hosts a podcast series that highlights the stories of women who have broken through barriers to succeed in their respective industries. She recently interviewed Abhilasha Ramasamy, a researcher with substantial experience in pharma and health economics and outcomes research. She […]
ICER Reveals Final Evidence Report on Three Multiple Myeloma Therapies
The Institute for Clinical and Economic Review (ICER) has announced a Final Evidence Report evaluating three therapies for use in multiple myeloma. ICER determined efficacy and cost-effectiveness of idecabtagene vicleucel, ciltacabtagene autoleucel, and belantamab mafodotin-blmf. Additional […]
Podcast on Succeeding as a Woman in Biotech and Business
Erin Jewell Consulting offers a podcast series highlighting the stories of women from different industries. A new podcast featuring Darla Wolf provides a look into the career of a businesswomen and technology expert. Wolf finds a balance between her business and non-profit work. She currently serves […]
Upcoming Webinar on Managing Unconscious Bias
Unconscious bias and microaggressions can lead to poor workplace culture and unhappy employees. A webinar will cover how to recognize and address unconscious bias appropriately. Speakers include President and CEO Laurie Halloran of Halloran Consulting Group and CEO Ramani Varanasi of X-Biotix […]
Aetion Announces $212 Million in Total Funding as RWE Momentum Builds
Aetion raised an additional $110 million in Series C funding, making its total funding $212 million. The real world evidence (RWE) company also noted a 100% customer renewal rate last year. RWE is becoming increasingly used in submissions to regulatory bodies, making Aetion attractive for both […]
HealthEconomics.Com President Leads Discussion on New Scientist.com’s Value, Evidence and Access Marketplace, Notes Substantial Cost Benefits
HealthEconomics.Com President Dr. Patti Peeples spoke with Scientist.com Category Directory Maria Negron and Senior Director of Business Development David Brown. Scientist.com, parent company of HealthEconomics.Com, recently announced an updated Value, Evidence and Access Marketplace. The […]
IQVIA Guide on RWD Applications in Drug Development Pipeline
IQVIA has released an eBook detailing when it’s appropriate to use real world evidence (RWE) and real world data (RWD). RWE integration offers researchers key benefits such as reduced costs and more efficient clinical trials. However, knowing when to utilize such data remains a challenge. The eBook […]
Upcoming Discussion on the Role of AI in Healthcare, COVID-19, and Equity
STAT recently published a report on artificial intelligence (AI), noting potential benefits such as lower healthcare costs and earlier disease diagnosis following its implementation. The report also highlighted downsides associated with AI, including privacy concerns and worsening health […]
Interactive Wednesday Webinar on Effective Medical Communication
Medical communication is becoming increasingly important for payers, pharma, and healthcare professionals. NetworkPharma will host a webinar this week on the value of improving medical communication, along with resources for medical writers. The webinar will take place at 12 PM BST on Wednesday, May […]
New Guide on Successfully Using RWE in Drug Development Pipeline
Using real world evidence (RWE) continues to be a valuable alternative to the traditional clinical trial. A new guide from United BioSource (UBC) provides insight into how to utilize RWE, generate RWE from patient registries, and understand the post-market space with RWE tools. “How do you […]
Can Improved QALYs Effectively Reduce Drug Prices?
Dan Ollendorf of Tuft’s Center for the Evaluation of Value and Risk in Health (CEVR) shared his thoughts on how the quality-adjusted life-year (QALY) measure could impact prescription drug prices. The QALY is a measure of the benefits of a drug on a patient’s life, although it has faced rejection […]
ISPOR’s Value in Health Discusses Economic Solutions to COVID-19 Pandemic
The International Society for Pharmacoeconomics and Outcomes Research (ISPOR)’s Value in Health journal published a themed collection of articles on COVID-19 economic outcomes. Although nonpharmaceutical interventions including social restrictions were necessary to reduce the spread of the […]
New Article Discusses 35 Oncology Drugs Receiving Accelerated Approval
An article published in the New England Journal of Medicine (NEJM) discusses 35 oncology drugs that received accelerated approval from the Food and Drug Administration. Drugs receiving this designation do not always demonstrate purported benefits in randomized clinical trials. The authors also […]
Amgen Leader Discusses Future Trends for Medical Affairs Professionals
Last year, the Medical Affairs Professional Society (MAPS) and Vice President of Amgen Europe Medical Affairs Dr. Isma Benattia announced results of a survey targeting medical affairs professionals. The survey was repeated earlier this year. Now, Dr. Isma Benattia shares her thoughts on how COVID-19 […]
MAPS Podcast on Virtual and Hybrid Events as COVID-19 Restrictions Ease
Medical Affairs Professional Society (MAPS) recently hosted a podcast with support from Impetus Digital. Impetus Digital CEO and Co-Founder Natalie Yeadon shared her thoughts on challenges that medical affairs professionals have faced as virtual networking replaced in-person events during the […]
Non-Legislative and Legislative Actions Could Reduce High Prescription Drug Prices
Reducing prescription drug prices in the United States continues to be a point of contention. Although legislative measures are expected to be proposed at the federal level, some policies might fall outside of legislation due to budget reconciliation regulations. When and how these non-legislative […]
Cytel Blog on Applying Bayesian Methods to COVID-19 Clinical Trials
A Cytel blog post discusses how Bayesian methods have impacted COVID-19 vaccine clinical trials. Using Bayesian statistics can improve study efficiency while still providing robust evidence regarding outcomes. In addition, the increasing use of these methods in clinical trials is expected to […]
Lead Author of PRISMA 2020 Statement Discusses Research and Publication Trends
In a recent discussion with Matt Page, lead author of the Preferred Reporting Items for Systematic reviews and Meta-Analysis (PRISMA) 2020 Statement, he discusses why the 2009 report required updates. He notes that an industry-wide recognition of bias, newly developed research trends, and a greater […]
ICER Publishes Draft Evidence Report on Alzheimer’s Disease Drug
The Institute for Clinical and Economic Review (ICER) published a Draft Evidence Report regarding Biogen’s aducanumab. The drug is designed to treat Alzheimer’s disease and cost-effectiveness analyses indicate a modest improvement compared to other medications. However, the drug’s efficacy remains […]
